Interest in the treatment of acute, systemic staphylococcal infections has been focused, in recent years, on the value of specific antitoxin and of the drugs of the sulfonamide group. The chief object of this study was to evaluate further the effectiveness of antitoxin, sulfapyridine, sulfathiazole, and sulfamethylthiazole in acute staphylococcal infection of mice.
Long and Bliss,20 and Mellon, Gross, and Cooper,24 in their monographs, have reviewed the conflicting evidence on the action of sulfanilamide, neoprontosil, and other early derivatives which have not found satisfactory clinical application. The reported experimental work on the action of sulfapyridine, sulfathiazole, and sulfamethylthiazole has held out greater promise of success against the staphylococcus. Whitby37 reported slight protective action with sulfapyridine against staphylococcal infection in mice, but experimental detail was omitted. Bliss and Long4 demonstrated a significant prolongation in the life of mice treated with sulfapyridine following intravenous infection. Mayer23 similarly observed some action in a small group of mice infected intraperitoneally, after they had been rendered more susceptible by mucin. Barlow and Homburger2 infected mice intravenously with 800 million organisms, and found sulfathiazole and sulfamethylthiazole effective in prolonging life and in preventing the development of internal abscesses or in their healing. They further noted, in groups of 20 mice observed for 20 days, that sulfamethylthiazole was superior to sulfathiazole, and that both were considerably more effective than sulfapyridine. Bliss and Ott,5 subjecting mice to severe intravenous infection, found negligible survival in 30 days, but significant prolongation of survival time, with sulfapyridine, sulfathiazole, and sulfamethylthiazole. The last two were equally effective and superior to sulfapyridine. Rake and McKee,30 studying intraperitoneal infection in mice rendered more susceptible by mucin, found, at the end of 31 days, little if any activity on the part of sulfapyridine, but definite protection afforded by the thiazole compounds, with sulfathiazole superior to sulfamethylthiazole. Evidence of persistence of staphylococci in internal organs was noted in 14 per cent of the sulfathiazole survivors and in 25 per cent of the sulfamethylthiazole group.
Some clinical data have accumulated in support of the actiQn of these compounds in severe staphylococcal infections. These, to date, have consisted in reports of isolated cases. Success in clearing the blood stream and in arresting the underlying process with sulfapyridine has been reported by Maxwell,22 O'Brien and McCarthy, 28 Fenton and Hodgkiss," Abramson and Flacks,' Goldberg and Sachs,"3 and others. Success in the clinical therapy of staphylococcal sepsis with sulfamethylthiazole was first reported by Herrel and Brown."5 The total number of reported cases is at present too small and the period of follow-up observation as yet too brief to warrant a final opinion as to the clinical effectiveness of these agents.
The question of the value of staphylococcal antitoxin in the treatment of acute infections with this organism is intimately bound up with the problem of the relative importance of the antitoxic, antibacterial, and, indeed, unknown factors in staphylococcal immunity. It is further complicated by the multiplicity of toxic principles isolated from this organism, and the, as yet, unestablished relative importance of these toxins in human infections. This problem has recently been brought to the fore by such studies as those of Valentine85 86 on the significance of the antileukocidin response in severe staphylococcal infections.
It is beyond the scope of this report to enter into discussion of these problems. The most convincing laboratory proof of the value of antitoxic serum must be sought in experiments designed to test its ability to prolong life or to protect completely the experimental animals. It is with this phase of the problem that the present study is primarily concerned, since review of the literature reveals that this aspect has received relatively limited consideration.
Burnet was among the first to note the ability of staphylococcal antitoxin to prolong the life of rabbits infected intravenously, although all animals ultimately succumbed. Connor and McKie8 protected completely a few rabbits against similar infection, but no experimental detail was presented. Bonnet, Thieffry, and Montefiore,6 likewise working with intravenous infection in rabbits, noted that 5 control animals died within 2 to 16 days; when 2500 units of antitoxin were administered 24 hours before the infection, 5 rabbits survived 3, 7, 14, 27, and 80 days, respectively. When the antitoxin was given simultaneously, two animals died in 3 and 27 days, respectively; three were living at 60 days, and one at the end of 90. Parish, O'Meara, and Clark29 had essentially similar experience with a few rabbits, and observed some prolongation in the life of mice infected intraperitoneally. Rigdon3' reinvestigated this problem in rabbits, testing the effect of a single dose before infection, multiple doses after intravenous inoculation, and the combination of these procedures. Although a marked prolongation of life was achieved, the therapy did not avert the development of the internal pyogenic foci. Nelis,26 on the other hand, failed to protect animals significantly with antitoxin against infections with living staphylococci. In an extensive study of staphylococcal immunity, Kitching and Farrell'8 noted a marked protective action on the part of antitoxin against intraperitoneal staphylococcal infection in mice when the antitoxin was given 18 hours before the infecting dose. However, their period of recorded observation was limited to 24 hours, although they claim that animals surviving this long are likely to live indefinitely.
While the number of animals used in most of the above reports has been small, and adequate dosage of antitoxin perhaps not always administered, the evidence certainly suggests that antitoxin exerts some protective action against infections with living staphylococci.
Of some interest is the attempt of De and Basu9 to evaluate the combined effect of sulfanilamide, antitoxin, and antibacterial serum in intraperitoneal staphylococcal infection in mice. A synergistic action was noted, although the number of mice in each group was limited to 12, and the total period of observation to only 4 days. Clinically, Meyer25 reported "cures" in 3 apparently hopeless cases of severe staphylococcal sepsis complicating prostatic abscess, osteomyelitis, and pelvic infection, respectively, when sulfanilamide and antitoxin therapy were combined. The hope of controlling infections by the combined use of immunological and chemotherapeutic agents has been frequently expressed since the advent of the newer drugs, and has already found application in other fields. Methods The organism employed was a hemolytic Staphylococcus aureus isolated from the blood stream of a patient suffering from osteomyelitis. This strain, named "T3," fermented mannite, coagulated rabbit plasma, and under special conditions of growth, produced for human blood a leukocidin active in a dilution of 1:25, and for rabbit blood a hemolysin active in a dilution of 1:50.* Its mouse virulence was increased by three intratesticular passages, as suggested by Duran-Reynals.'0 In order to obtain effective concentrations, the organisms were grown on infusion agar plates and incubated for from 18 to 24 hours. At the end of this period, 5 to 10 cc. of infusion broth were added to the plates, the organisms were brought into suspension with a platinum loop, and the agar plates were re-incubated for an additional 3 to 6 hours. The bacterial counts were determined by the 24 to 48 hours in a majority of the animals receiving the effective dose. Attempts by these routes to produce an illness with a subacute course met with failure. Reduction below the acutely lethal dose led to a sharp drop in the mortality rate rather than to the establishment of a fatal, but more chronic infection. Efforts to duplicate Hoyle's17 results in the production of staphylococcal pneumonia by intranasal instillation under ether were unsuccessful, possibly due to a difference in the strain of organism used. The subcutaneous route was finally selected as perhaps representing a portal less foreign to the staphylococcus than the other modes of inoculation, and one which would lend itself to observation of the local lesion produced. All inoculations were carried out in the anterior abdominal wall.
Powdered sulfapyridine, sulfathiazole, and sulfamethylthiazole were administered subcutaneously in the form of a 5 per cent acacia-saline suspension, in concentrations of either 20 or 40 mg. per cc. While the concentration of these compounds was not determined in any of the experimental animals, preliminary values were obtained on the pooled heart blood of three mice for each determination of blood level. Free sulfapyridine levels were determined on two sets of mice; in one set at intervals after a single dose of 20 mg., in the other after three doses of 20 mg. each, given at intervals of 5 hours (Table 1A) . Free and total sulfathiazole levels were obtained at intervals after a single dose of 20 mg. of sulfathiazole, and two levels after two doses of 20 mg. each, given at an interval of 8 hours (Table 1B) . It is noteworthy that adequate blood levels were attained by the introduction of these drugs subcutaneously, and that with a repetition of doses as indicated, a cumulative effect was produced, leading to higher blood concentration maintained for a longer period of time. It is therefore very likely that in the experiments presented in Table 2 , adequate blood levels were maintained whenever more than one dose was administered in the course of 24 hours. Animals receiving the sulfonamide compounds only, in doses equal to those used in the experiments, showed no evidence of intoxication.
Lederle Staphylococcus Antitoxin (Globulin Modified), containing 20,000 International Units of antilysin per vial, or approximately 900 to 1000 units per cc., and about 6 K Valentine units of antileukocidin,3 was used exclusively.
The therapeutic agents were administered subcutaneously on the dorsal aspect, without coming into direct contact with the infected area on the ventral surface.
The control groups received, during the first 24 hours following infection, an amount of fluid (saline or acacia-saline) equivalent to that of the treated groups. The maximum volume of fluid administered in the course of therapy was well tolerated by a fluid control group of 5 mice.
Experimental results
The results of therapy with antitoxin, sulfapyridine, sulfathiazole, and sulfamethylthiazole are summarized in Table 2 .
Sulfapyridine alone. When a single dose of 20 mg. per day was given (Exp. I) no significant protection was obtained. The administration of three doses of 20 mg. within the first 18 hours after infection (Exp. II), followed by 20 mg. b.i.d. for three days and then 20 mg. daily for three days, led to a notable increase in survivors during the first week, although ultimately most of these animals succumbed. The most striking early protective action was noted in Exp. III, when a 20 mg. dose was given half an hour before the infecting dose, even though the next therapeutic dose was withheld for 18 hours. This degree of protection during the first week was not duplicated in any of the other experiments and might have been influenced by the strain of mice used,-in this instance the highly inbred "Strain A." In spite of the preliminary dose of sulfapyridine given 2 hours before infection in Exp. IV, using, however, almost twice the infecting dose, a different strain of mice, and smaller daily dosage of sulfapyridine, no striking early protection was afforded.
The question of the effect of delayed therapy was then investi- gated. Accordingly, in Exps. V and VI, one group of mice did not receive the first dose of sulfapyridine until 6 hours after the infecting dose, while the other group in each experiment received an earlier dose 5 minutes and 2 hours respectively, after the infection. No significant difference in ultimate survival was noted.
Further experience with sulfapyridine is provided by Exps. VII, X, and XIII. These require no further comment, except to point out that the failure of sulfapyridine alone to exert any action in Exp. X may have been due to the high infecting dose in a younger group of mice, and the reduction in the daily sulfapyridine dose to a level which, however, has been found adequate for the control of intraperitoneal pneumococcal infection in mice. '4 Sulfamethyithiazole and sulfathiazole. The therapeutic results with the thiazole derivatives are presented in Exps. XI to XIV. Throughout the duration of Exp. XII, sulfamethylthiazole exerted a highly significant degree of protection, and even the reduction of each therapeutic dose to 10 mg. (Exp. XI) still left it some favorable action. In Exp. XIII, in which a higher infecting dose was used, the therapeutic result was considerably diminished, though still significant. Sulfathiazole (Exp. XIII) exerted essentially the same action as the other therapeutic agents, but its effectiveness was of a lower order in Exp. XIV despite a reduction in the infecting dose.
Antitoxin alone. Preliminary titrations were carried out with Lederle Staphylococcus Antitoxin (Globulin Modified) on a group of 200 mice. These failed to demonstrate any significant protective action against 6 to 10 billion organisms subcutaneously when less than 0.5 cc. (about 500 International Units) was administered subcutaneously or intraperitoneally. Some prolongation of life was noted when 0.5 cc. were used. Intraperitoneal administration of antitoxin was abandoned in preference to the subcutaneous route, since the former was very irritating to the mouse and led to a marked hyperkinetic response. A dose of 0.8 cc. or of 1 cc. was therefore used. However, the latter dose is close to the toxic dose, especially for a mouse less than 20 gm. in weight. Severe early reactions have been observed, consisting in rigor, weakness, and, rarely, paraplegia and rapid death.
The results of antitoxin therapy are presented in Exps. VII, X, XIII, and XIV. The significance of these findings statistically in terms of 48-hour, 7-day, and ultimate survival, is presented elsewhere (Table 5 ). It is of interest here to point out the superiority of antitoxin over the chemotherapeutic agents during the first 24 hours after infection. This may be illustrated by Exp. XIV (Table 3) . This effect has constituted the most striking difference between the action of the antitoxin and the drugs of the sulfonamide group. A small number of animals are overwhelmed within 3 to 9 hours after infection regardless of therapy, and the differences due to therapy do not manifest themselves until after 12 hours following infection.
Antitoxin plus sulfapyridine. In Exps. VII to X are summarized the results with combined antitoxin and sulfapyridine therapy. It appears that this form of therapy afforded maximum protection against acute death (48 hrs.) when compared to the effect of these agents separately, although the ultimate protection was not significantly superior to antitoxin alone. The relatively poor results of Exp. X, when compared to those of the three preceding ones, may again be attributed to the smaller sulfapyridine doses, the larger infecting dose, and the fact that the mice used, being smaller, may have been more susceptible to the toxic action of the antitoxin.
Antitoxin plus sulfathiazole. The results of combined antitoxin and sulfathiazole therapy are presented in Exp. XIV. Although this proved superior to antitoxin and sulfathiazole alone during the acute phase, it lost this advantage ultimately, with the final protection not significantly different from that of antitoxin, and not statistically superior to sulfathiazole alone.
The results of Exps. I to XIV are summarized in Table 4 . These findings were submitted to statistical analysis by the "Chi Square" test. The results are presented in Table 5 . From these data, the following chief conclusions may be drawn: Sulfapyridine, sulfathiazole, sulfamethylthiazole, and staphylococcal antitoxin, as well as the combined use of antitoxin with sulfapyridine and sulfathiazole respectively, afforded statistically significant protection throughout the duration of the experiment when compared to the control group. Antitoxin proved superior to sulfapyridine and sulfathiazole but did not surpass sulfamethylthiazole. Sulfapyridine and sulfathiazole presented essentially the same order of activity.
The combined use of sulfapyridine and antitoxin was superior to sulfapyridine alone throughout, but definitely surpassed antitoxin only during the acute phase. Sulfathiazole and antitoxin therapy combined was superior to these agents alone only during the acute phase.
Discussion
Subcutaneous infection with large doses of staphylococci in mice leads to local and general effects. At the site of inoculation there appear the phenomena of congestion, induration, necrosis, ulceration, suppuration, and finally, healing by scar formation. The degree of involvement is quite variable, and may extend over the entire abdominal and thoracic wall. Likewise, the rate at which these processes develop varies markedly from animal to animal, although, in general, ulceration does not appear until some 7 days after infection. At death, inspissated purulent material may be found extending a considerable distance beyond the boundaries of the ulcer. Rarely, an ulcer may perforate into the peritoneal cavity. In surviving animals, healing by fibrosis is usually complete within 30 days, leaving only an uninfected scar.
Death within 24 to 48 hours is the most constant general effect of an adequate dose of virulent staphylococci. As previously demonstrated (Table 3 ) a small number of mice are overwhelmed within a few hours of inoculation. Although the heart blood and organs have been found consistently positive for staphylococci in animals dying within 48 hours of inoculation, no gross pathology has been noted at this time. The more chronic manifestations, as observed in treated and in occasional untreated animals not dying acutely, consisted mainly in renal abscesses, splenomegaly, and areas of pulmonary congestion or consolidation, with or without pleural effusion. Rarely, myocardial abscesses have been noted. These findings have been confirmed by microscopic sections. No gross involvement of the vertebral column or of the brain has been observed in animals developing hind-limb paralysis.
The occurrence of paralysis of the hind limbs deserves special consideration. It has been observed to a slight extent in the control groups receiving staphylococci only, but has been most striking in the animals whose life has been prolonged by chemotherapy, less so in the groups receiving antitoxin alone. Most of the animals developing any marked degree of this disturbance succumb to the infection. Uninfected mice receiving only the therapeutic agents failed to develop this sign. Nelis26 has produced hind-limb paralysis in experimental animals by the inoculation of staphylococcus toxin into the femoral artery, and has neutralized this effect by specific antitoxin. It may be suggested, therefore, that the in vivo liberation of toxin may account for the behavior of the different experimental groups. The control groups succumb too acutely to manifest it except to a minimal extent, and the surviving animals may be regarded as possessing a high order of natural immunity which protects against any of the general manifestations of staphylococcal infection. The mice treated with the chemotherapeutic agents are probably not protected against any toxic action of the staphylococcus, and while life is prolonged or saved by some other mechanism, the liberation of toxin in vivo is given an opportunity to proceed unchecked in some of the animals. Mice receiving antitoxin, on the other hand, have this toxic action neutralized in part, and hence the paralysis is inhibited, though not completely averted in all of the animals. This phenomenon, however, requires further investigation, since no direct proof is as yet available as to its cause.
Those animals, treated and untreated, which succumbed to the infection were found to harbor the organism in the blood stream; failure to isolate staphylococci at death was rare. At the conclusion of Exps. VII and VIII, cultures were made from the heart blood, kidney, and spleen of all surviving mice, and no evidence of persisting infection was found. Similarly, at the conclusion of Exps. XII and XIII, selected mice were autopsied and cultured, as above, but no pyogenic foci were demonstrated. However, the possibility of a microscopic focus somewhere cannot be entirely excluded, since, as Forssman"2 has pointed out, osteomyelitis of the vertebral column may not become manifest until as late as a year following intravenous infection of rabbits with staphylococci. Whenever surviving animals were killed and autopsied at the termination of the experiments, no gross foci were noted.
Analysis of the experiments presented in Table 2 reveals a marked degree of variation in the results obtained on different occasions with the same therapeutic agent. Doubtless, factors such as the nature and mode of therapy, the dosage of the staphylococcus and its age, the strain and weight of the mice, as well as other influences whose operation is not established, have contributed to this fact. It serves to re-emphasize the need of adequate numbers of experimental animals before reaching conclusions with regard to the action of the agents investigated.
Although the total results summarized in Table 5 point to a statistically significant effectiveness on the part of all agents tested, the degree of protection has fallen considerably short of that reported for chemotherapeutic agents with such organisms as pneumococci and streptococci. The relative lack of virulence of the staphylococcus for the mouse and the consequent necessity of using a large dose to produce a lethal infection may well have contributed to the apparently reduced efficacy of the agents here tested, since it has been shown that the effectiveness of sulfonamide compounds may vary directly with the virulence and dosage of a susceptible organism.20' 27 The interpretation of animal experiments in terms of human infection is always subject to limitations, and particularly is this true here. In the first place, the type of infection produced in the mouse in the present study simulates primarily the acute, fulminating type of disease to which man may succumb even before the appearance of pyogenic foci, and cannot be interpreted as casting any light on the possible action of these agents in the chronic type of infection. A further factor which must be weighed is the well-known natural immunity of the mouse to staphylococci, since this may determine ultimate survival of the resistant animal and yet be inoperative in the relatively susceptible human subject. Consequently, one Rigdon32 has demonstrated, in a study of subcutaneous staphylococcal infection in mice, that the pathological changes produced are identical with those caused by the injection of staphylococcal exotoxin, and are inhibited by antitoxin. One must note, however, that with the doses used in the present study the factor of bacterial invasion cannot be overlooked. Thus, when 5 billion organisms were inoculated subcutaneously, and the animals were sacrificed at onehalf hour, one hour, and two hours respectively, all cultures of the heart blood, spleen, and kidneys revealed an abundant growth of staphylococci. However, the ability of antitoxin to save many animals from acute death, and to protect a smaller number indefinitely, favors the view that the toxin plays a vital role in the pathogenicity of the staphylococcus. One should emphasize, however, that the present available antitoxin has a potent antilysin titer, antileukocidin in high concentration, and perhaps other as yet unidentified fractions. While the protection afforded by this product, within the limits of the experiments presented, seems definite, it cannot be attributed to the antilysin content without exploring the possible role of the other principles.
Neither the antitoxin nor the chemical agents were able to avert the development of lesions at the site of inoculation in the subcutaneous tissues. Likewise, internal pyogenic foci were not infrequently noted in treated animals succumbing to the infection. With regard to the local lesion, no conclusion may be drawn as to the possible modifying effect of therapy when compared to the controls, since the majority of the untreated mice succumb before a lesion fully develops at the site of inoculation.
It should be noted that all experiments presented in this study were carried out with but one strain of staphylococcus. Such studies as those of Spink34 and Rigdon33 on the action of sulfanilamide and sulfapyridine on different strains of the staphylococcus in vitro, as well as the report of MacLean, Rogers, and Fleming2' on the different action of sulfapyridine in vivo and in vitro against various strains of pneumococci, raise the possibility that other strains might be affected differently by the therapeutic agents tested.
Summary
Studies are presented on the nature and therapy of acute subcutaneous infection of mice with a single strain of hemolytic Staphylococcus aureus.
Staphylococcus antitoxin (Globulin Modified), sulfapyridine, sulfathiazole, and sulfamethylthiazole, all led to statistically significant protection.
A single early dose of antitoxin proved superior to sulfapyridine and sulfathiazole, but did not surpass the activity of sulfamethylthiazole.
The combined use of sulfapyridine and antitoxin was superior to sulfapyridine alone, but exceeded the activity of antitoxin definitely only during the acute phase.
Combined sulfathiazole and antitoxin therapy was superior to these agents separately only during the acute phase.
The best ultimate results were obtained by the combined use of sulfapyridine and antitoxin, and by sulfamethylthiazole.
The limitations of the experimental methods used are presented.
